Virscio is a translational research organization providing in vivo NHP safety and disease modeling and related preclinical research and development services, including histopathology in all species. We specialize in the fields of central nervous system, ophthalmology, cardiovascular, metabolic and dermatologic diseases, and have advanced preclinical toxicology and efficacy programs for sponsors around the world. We work with pharmaceutical and biotechnology companies, and consultants and academic teams to reduce development risk and define the most effective path to value inflection and clinic.
Looking for a particular Virscio employee's phone or email?
The Virscio annual revenue was $16.8 million in 2026.
Matthew Lawrence is the CEO and CSO of Virscio.
39 people are employed at Virscio.
Virscio is based in New Haven, Connecticut.
The NAICS codes for Virscio are [54171, 541, 54, 541714, 5417].
The SIC codes for Virscio are [87, 873].